DD147005A5 - Verfahren zum nachweis bakterieller infektionen - Google Patents

Verfahren zum nachweis bakterieller infektionen Download PDF

Info

Publication number: DD147005A5
Authority: DD; German Democratic Republic
Prior art keywords: bacterial; bacterial enzymes; substrate; infections; sample
Prior art date: 1979-10-19

Application number

DD79216966A

Other languages

German (de)

English (en)

Inventor

Amalia Romano

Original Assignee

Amalia Romano

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-10-19

Filing date

1979-11-16

Publication date

1981-03-11

1979-11-16 Application filed by Amalia Romano filed Critical Amalia Romano

1981-03-11 Publication of DD147005A5 publication Critical patent/DD147005A5/de

Links

238000000034 method Methods 0.000 title claims abstract description 15
208000035143 Bacterial infection Diseases 0.000 title claims abstract description 11
208000022362 bacterial infectious disease Diseases 0.000 title claims abstract description 11
102000004190 Enzymes Human genes 0.000 claims abstract description 27
108090000790 Enzymes Proteins 0.000 claims abstract description 27
230000001580 bacterial effect Effects 0.000 claims abstract description 25
239000000758 substrate Substances 0.000 claims abstract description 14
239000000463 material Substances 0.000 claims abstract description 12
239000003242 anti bacterial agent Substances 0.000 claims abstract description 11
230000009385 viral infection Effects 0.000 claims abstract description 10
208000036142 Viral infection Diseases 0.000 claims abstract description 9
229940088710 antibiotic agent Drugs 0.000 claims abstract description 9
239000000126 substance Substances 0.000 claims abstract description 9
230000015572 biosynthetic process Effects 0.000 claims abstract description 5
208000015181 infectious disease Diseases 0.000 claims abstract description 5
238000010186 staining Methods 0.000 claims abstract description 5
238000001514 detection method Methods 0.000 claims abstract description 4
210000000056 organ Anatomy 0.000 claims abstract description 4
229920004449 Halon® Polymers 0.000 claims abstract description 3
229950003937 tolonium Drugs 0.000 claims description 3
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 3
230000003115 biocidal effect Effects 0.000 claims description 2
102000014150 Interferons Human genes 0.000 abstract description 12
108010050904 Interferons Proteins 0.000 abstract description 12
229940079322 interferon Drugs 0.000 abstract description 12
230000003612 virological effect Effects 0.000 abstract description 6
230000000840 anti-viral effect Effects 0.000 abstract description 5
208000024780 Urticaria Diseases 0.000 abstract 1
229940088598 enzyme Drugs 0.000 description 18
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229920000936 Agarose Polymers 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
108010003272 Hyaluronate lyase Proteins 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000001974 Hyaluronidases Human genes 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
230000028161 membrane depolarization Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 2
229940053050 neomycin sulfate Drugs 0.000 description 2
238000005057 refrigeration Methods 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical class [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
-1 aliphatic alcohols Chemical class 0.000 description 1
230000003431 anti-prostaglandin Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
230000003328 fibroblastic effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940049018 mycostatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
229960003962 trifluridine Drugs 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears

Landscapes

Health & Medical Sciences (AREA)
Ophthalmology & Optometry (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DD79216966A 1979-10-19 1979-11-16 Verfahren zum nachweis bakterieller infektionen DD147005A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/DE1979/000123 WO1981001102A1 (fr)	1979-10-19	1979-10-19	Remede pour le traitement des infections virales de l'oeil et d'autres organes

Publications (1)

Publication Number	Publication Date
DD147005A5 true DD147005A5 (de)	1981-03-11

Family

ID=6699862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79216966A DD147005A5 (de)	1979-10-19	1979-11-16	Verfahren zum nachweis bakterieller infektionen

Country Status (4)

Country	Link
EP (1)	EP0039325A1 (it)
DD (1)	DD147005A5 (it)
IT (1)	IT1126570B (it)
WO (1)	WO1981001102A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0080032A3 (en) *	1981-11-20	1985-11-13	Enzo Biochem, Inc.	Pharmaceutical preparation for treating herpetic lesions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1091245A (en) *	1963-12-09	1967-11-15	Pfizer & Co C	Method for inducing resistance to viral infections in an animal
GB1170929A (en) *	1965-12-28	1969-11-19	Glaxo Lab Ltd	Antirival Nucleic Acids.
BE758977A (fr) *	1969-11-17	1971-05-17	Glaxo Lab Ltd	Procede biochimique
FR2134292A1 (en) *	1971-04-30	1972-12-08	Inst Nat Sante Rech Med	Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
SE7612343L (sv) *	1975-11-07	1977-05-08	Beecham Group Ltd	Metod for behandling av djur
FR2374042A1 (fr) *	1976-06-04	1978-07-13	Merieux Inst	Nouveau medicament immunostimulant et son procede de preparation
GB2016015B (en) *	1978-01-22	1982-05-06	Hayashibara Co	Method of preparing interferon and preparations containing interferon
DE2967049D1 (en) *	1978-04-11	1984-07-19	Efamol Ltd	Pharmaceutical and dietary composition comprising gamma-linolenic acids

1979
- 1979-10-19 WO PCT/DE1979/000123 patent/WO1981001102A1/de not_active Ceased
- 1979-10-19 EP EP79901504A patent/EP0039325A1/de not_active Withdrawn
- 1979-11-16 DD DD79216966A patent/DD147005A5/de unknown
- 1979-12-07 IT IT28000/79A patent/IT1126570B/it active

Also Published As

Publication number	Publication date
IT7928000A0 (it)	1979-12-07
IT1126570B (it)	1986-05-21
WO1981001102A1 (fr)	1981-04-30
EP0039325A1 (de)	1981-11-11

Publication	Publication Date	Title
DE69607749T2 (de)	2000-07-27	Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
DD250053A5 (de)	1987-09-30	Verfahren zur herstellung einer synergistischen mischung von interferonen und tumor-nekrose-faktor
DE3034142C2 (it)	1990-02-01
DE1617805C3 (de)	1974-08-22	Verfahren zur Gewinnung von Lysozym aus Eiweiß
DE1260080B (de)	1968-02-01	Verfahren zur Reinigung von Interferon
DE3434122A1 (de)	1985-06-05	Verfahren zur herstellung von interferon
DD147005A5 (de)	1981-03-11	Verfahren zum nachweis bakterieller infektionen
DE1940130C2 (de)	1983-12-08	Verfahren zur Reinigung von Insulin, nach diesem Verfahren gereinigtes Insulin und dessen Verwendung
EP0017867A2 (de)	1980-10-29	Arzneimittel zur Stimulation der Proliferation von Leberzellen und Leberschutz- und Wachstumsfaktor
DE69119576T2 (de)	1997-03-27	Verfahren zur Abtrennung, Identifizierung und Quantifizierung von Isoenzymen und Isoformen der alkalischen Phosphatase
DE2453624A1 (de)	1975-05-15	Arzneimittel
DE2234832C2 (de)	1986-02-13	Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate
DE1620629B2 (de)	1979-08-02	Verwendung eines Salzes von 2-Merkaptoäthansulfonsäure zur Herstellung von Mukolytica
DE3249215T1 (de)	1983-11-17	Verfahren zur herstellung von humanem (gamma)-interferon
DE1942900C3 (de)	1978-06-22	Verfahren zur Abtrennung von L-Asparaginase aus Bakterienkulturen, danach hergestellte L-Asparaginase und diese enthaltendes therapeutisches Mittel
DE1467743A1 (de)	1968-12-12	Verfahren zur Herstellung eines Praeparats mit verlaengerter Vitamin B 12-Wirkung
DE4217916C2 (de)	1995-05-18	N-Alkylamin- und N-Arylalkylaminderivate von Heparin, Verfahren zu ihrer Herstellung und ihrer Verwendung
DE60119130T2 (de)	2006-11-30	Behandlung von tumoren mit azetylenen disubstituiert mit einer heteroaromatischen gruppe und mit einer substituierten thiochromanyl gruppe in kombination mit anderen antitumormitteln
AT345482B (de)	1978-09-25	Verfahren zur herstellung von neuen insulinderivaten
DE951724C (de)	1956-10-31	Verfahren zur Herstellung injizierbarer Derivate des Gramicidins S
Tandler et al.	1918	C. Bücherbesprechungen.
DE1000963C2 (de)	1957-07-25	Verfahren zur Herstellung von biologisch aktiven, Vitamine der B-Gruppe enthaltenden Zubereitungen
Böhmer et al.	1971	Disaccharidasenaktivität des jejunums subtotal pankreatektomierter ratten
EP0135797A2 (de)	1985-04-03	Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
DE2129130C3 (de)	1981-02-12	6,6-Dimethyl-4-oxo-2-formyl- [3,1,1] -bicyclo-2hepten, Verfahren zu seiner Herstellung und seine Verwendung